KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Moderna (MRNA) Net Margin (2017 - 2026)

Moderna (MRNA) has disclosed Net Margin for 10 consecutive years, with 345.24% as the latest value for Q1 2026.

  • For Q1 2026, Net Margin rose 55383.0% year-over-year to 345.24%; the TTM value through Mar 2026 reached 143.55%, down 3568.0%, while the annual FY2025 figure was 145.16%, 3512.0% down from the prior year.
  • Net Margin hit 345.24% in Q1 2026 for Moderna, down from 121.83% in the prior quarter.
  • Across five years, Net Margin topped out at 60.29% in Q1 2022 and bottomed at 899.07% in Q1 2025.
  • Average Net Margin over 5 years is 231.38%, with a median of 115.94% recorded in 2024.
  • Year-over-year, Net Margin tumbled -70784bps in 2024 and then soared 55383bps in 2026.
  • Moderna's Net Margin stood at 28.82% in 2022, then plummeted by -73bps to 7.72% in 2023, then crashed by -1602bps to 115.94% in 2024, then fell by -5bps to 121.83% in 2025, then tumbled by -183bps to 345.24% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 345.24%, 121.83%, and 19.69% for Q1 2026, Q4 2025, and Q3 2025 respectively.